Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 30, 2015 7:33 AM ET


Company Overview of AV Therapeutics, Inc.

Company Overview

AV Therapeutics, Inc. develops cancer therapeutics and immunotherapeutic vaccines. The company identifies and patents the Capridine, a chemotherapeutic drug that has shown in preclinical models to have specific activity against prostate and colon cancer. Its cancer therapeutics and immunotherapeutic vaccines could be used together with prevalent treatment modalities, such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. AV Therapeutics, Inc. was founded in 2011 and is headquartered in New York, New York.

20 East 68th Street

Suite 204

New York, NY 10065

United States

Founded in 2011



Key Executives for AV Therapeutics, Inc.

Chairman, Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
Age: 66
Compensation as of Fiscal Year 2013.

AV Therapeutics, Inc. Key Developments

AV Therapeutics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 09:30 AM

AV Therapeutics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 09:30 AM.

AV Therapeutics Completes GMP Synthesis of Its Lead Prostate Cancer Chemotherapeutic Drug, Capridine

AV Therapeutics, Inc. announced the completion of GMP synthesis of its lead prostate cancer drug, Capridine. Analysis of the product indicated the Capridine to be 99.8 % pure and NMR (nuclear magnetic resonance) analysis showed great conformity of the scaled-up product. This achievement was possible with the help of the colleagues at Davos Pharma and the scientists at Anthem Biosciences, under the supervision and guidance of Dr. Raj Tiwari, Chief Scientific Officer of AV Therapeutics. A Certificate of Analysis has been generated that outlines all of the analyses and structure of the synthesized product. This GMP product was used to generate a limited toxicity profile, and scientists at AV Therapeutics are currently analyzing the data.

AV Therapeutics, Inc. announced delayed 10-Q filing

On 11/14/2014, AV Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
Blue Belt Holdings, Inc. United States
Gulf Nuclear of Louisiana Inc. United States
Prexa Pharmaceuticals, Inc. United States
Kaperio, Inc. United States
Concortis Biosystems, Corp. United States

Recent Private Companies Transactions

Private Placement
April 4, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AV Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at